JP6072725B2 - イン・サイチュシールを有する経皮送達デバイス - Google Patents
イン・サイチュシールを有する経皮送達デバイス Download PDFInfo
- Publication number
- JP6072725B2 JP6072725B2 JP2014097353A JP2014097353A JP6072725B2 JP 6072725 B2 JP6072725 B2 JP 6072725B2 JP 2014097353 A JP2014097353 A JP 2014097353A JP 2014097353 A JP2014097353 A JP 2014097353A JP 6072725 B2 JP6072725 B2 JP 6072725B2
- Authority
- JP
- Japan
- Prior art keywords
- layer
- psa
- overlay
- pib
- release liner
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000037317 transdermal delivery Effects 0.000 title description 17
- 238000011065 in-situ storage Methods 0.000 title description 6
- 239000010410 layer Substances 0.000 claims description 181
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 147
- 239000004480 active ingredient Substances 0.000 claims description 106
- 229920002367 Polyisobutene Polymers 0.000 claims description 85
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 58
- 238000000576 coating method Methods 0.000 claims description 40
- 239000011248 coating agent Substances 0.000 claims description 39
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims description 36
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 28
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 28
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 28
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 28
- 229940088597 hormone Drugs 0.000 claims description 25
- 239000005556 hormone Substances 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 23
- -1 alcohol ester Chemical class 0.000 claims description 22
- 229920000058 polyacrylate Polymers 0.000 claims description 22
- 239000000583 progesterone congener Substances 0.000 claims description 20
- 229940116333 ethyl lactate Drugs 0.000 claims description 18
- 239000003623 enhancer Substances 0.000 claims description 17
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 16
- 229940011871 estrogen Drugs 0.000 claims description 15
- 239000000262 estrogen Substances 0.000 claims description 15
- 239000004014 plasticizer Substances 0.000 claims description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 14
- 239000003906 humectant Substances 0.000 claims description 14
- 239000004310 lactic acid Substances 0.000 claims description 14
- 235000014655 lactic acid Nutrition 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 12
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 11
- 239000006260 foam Substances 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 10
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 10
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 claims description 10
- 150000001261 hydroxy acids Chemical class 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 238000013271 transdermal drug delivery Methods 0.000 claims description 10
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 8
- 229960005309 estradiol Drugs 0.000 claims description 8
- 229960004400 levonorgestrel Drugs 0.000 claims description 8
- 229920002635 polyurethane Polymers 0.000 claims description 8
- 239000004814 polyurethane Substances 0.000 claims description 8
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 7
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229960002568 ethinylestradiol Drugs 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229920001083 polybutene Polymers 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 5
- 239000002480 mineral oil Substances 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 5
- 239000004745 nonwoven fabric Substances 0.000 claims description 5
- 229920006267 polyester film Polymers 0.000 claims description 5
- 229920002313 fluoropolymer Polymers 0.000 claims description 4
- 239000002759 woven fabric Substances 0.000 claims description 4
- 239000011229 interlayer Substances 0.000 claims description 3
- 229920000098 polyolefin Polymers 0.000 claims description 3
- 229920006264 polyurethane film Polymers 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 229920003176 water-insoluble polymer Polymers 0.000 claims 2
- 210000003491 skin Anatomy 0.000 description 58
- 239000002998 adhesive polymer Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 16
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 229920000307 polymer substrate Polymers 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000003961 penetration enhancing agent Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 229920000728 polyester Polymers 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 229920002633 Kraton (polymer) Polymers 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 229920002799 BoPET Polymers 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 3
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- MJCGSKDRHVUFFD-PSKDZAHRSA-N 5-[(8R,9S,13S,14S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound [C@@H]12CCC(O)([C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3)CCCCC(=O)O MJCGSKDRHVUFFD-PSKDZAHRSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920005830 Polyurethane Foam Polymers 0.000 description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 229960002510 mandelic acid Drugs 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 206010002261 Androgen deficiency Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FFOPEPMHKILNIT-UHFFFAOYSA-N Isopropyl butyrate Chemical compound CCCC(=O)OC(C)C FFOPEPMHKILNIT-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 239000005041 Mylar™ Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003522 acrylic cement Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 150000002159 estradiols Chemical class 0.000 description 2
- BXOUVIIITJXIKB-UHFFFAOYSA-N ethene;styrene Chemical group C=C.C=CC1=CC=CC=C1 BXOUVIIITJXIKB-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 229960002826 levonorgestrel and ethinylestradiol Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001195 polyisoprene Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Natural products CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- 150000000307 17β-estradiols Chemical class 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical group CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- XOJWAAUYNWGQAU-UHFFFAOYSA-N 4-(2-methylprop-2-enoyloxy)butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCOC(=O)C(C)=C XOJWAAUYNWGQAU-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 229940124810 Alzheimer's drug Drugs 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000724705 Lucerne transient streak virus Species 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 229920005987 OPPANOL® Polymers 0.000 description 1
- 229920002402 Oppanol® B 100 Polymers 0.000 description 1
- 229920012485 Plasticized Polyvinyl chloride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- OKKRPWIIYQTPQF-UHFFFAOYSA-N Trimethylolpropane trimethacrylate Chemical compound CC(=C)C(=O)OCC(CC)(COC(=O)C(C)=C)COC(=O)C(C)=C OKKRPWIIYQTPQF-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- VQHQLBARMFAKSV-AANPDWTMSA-N [(8r,9s,13s,14s,17s)-3-acetyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(OC(C)=O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 VQHQLBARMFAKSV-AANPDWTMSA-N 0.000 description 1
- ZZAGLMPBQOKGGT-UHFFFAOYSA-N [4-[4-(4-prop-2-enoyloxybutoxy)benzoyl]oxyphenyl] 4-(4-prop-2-enoyloxybutoxy)benzoate Chemical compound C1=CC(OCCCCOC(=O)C=C)=CC=C1C(=O)OC(C=C1)=CC=C1OC(=O)C1=CC=C(OCCCCOC(=O)C=C)C=C1 ZZAGLMPBQOKGGT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- QAHOQNJVHDHYRN-SLHNCBLASA-N beta-Estradiol 17-acetate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 QAHOQNJVHDHYRN-SLHNCBLASA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- ZPOLOEWJWXZUSP-WAYWQWQTSA-N bis(prop-2-enyl) (z)-but-2-enedioate Chemical compound C=CCOC(=O)\C=C/C(=O)OCC=C ZPOLOEWJWXZUSP-WAYWQWQTSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229960001673 diethyltoluamide Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960004822 erythromycin phosphate Drugs 0.000 description 1
- FHXBMXJMKMWVRG-SLHNCBLASA-N estradiol acetate Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2CCC3=CC(OC(=O)C)=CC=C3[C@H]21 FHXBMXJMKMWVRG-SLHNCBLASA-N 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229920003049 isoprene rubber Polymers 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 1
- 229960001951 montelukast sodium Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AOJBACHWNDMRQP-UHFFFAOYSA-N n,n-diethyl-4-methylbenzenesulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(C)C=C1 AOJBACHWNDMRQP-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- FBCQUCJYYPMKRO-UHFFFAOYSA-N prop-2-enyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC=C FBCQUCJYYPMKRO-UHFFFAOYSA-N 0.000 description 1
- QTECDUFMBMSHKR-UHFFFAOYSA-N prop-2-enyl prop-2-enoate Chemical compound C=CCOC(=O)C=C QTECDUFMBMSHKR-UHFFFAOYSA-N 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00646—Medication patches, e.g. transcutaneous
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本願は、米国仮特許出願第60/948,757号(名称「Dermal Delivery Device with In situ Seal」、2007年7月10日出願)の利益を主張し、この出願は、すべての目的のためにその全体が本明細書に参考として援用される。
本発明は、全身性、局部性、または表面性投与のための皮膚への薬理学的または美容的な活性薬剤の送達の分野におけるものである。
経皮送達デバイスは、皮膚への適用のための接着性「パッチ」であって、多種多様な薬理学的および美容的な活性薬剤を送達するために使用される。そのようなパッチを使用して、経皮的に、すなわち、全身性治療のために皮膚を通して血流内に、あるいは局部性治療のために皮膚内または皮膚を通して、薬剤を送達することが可能である。また、そのようなパッチを使用して、美容的活性薬剤を含む局所性治療を投与することが可能である。
本発明は例えば、以下の項目を提供する:
(項目1)
経皮的薬物送達デバイスであって、
a.皮膚接触表面と非皮膚接触表面とを有し、揮発性成分を含む、活性成分(AI)層と、
b.該AI層の該皮膚接触表面に隣接する剥離ライナであって、該剥離ライナは、該揮発性成分に対して不透過性であり、それの周縁は、全方向に該AI層の周縁を超えて延在する、剥離ライナと、
c.該AI層の該非皮膚接触表面に隣接する感圧接着剤(PSA)を含む重層であって、該PSAは、該揮発性成分を吸収せず、それの周縁は、全方向に該AI層の周縁を超えて延在する、重層と
を含み、
該剥離ライナおよび該重層の該PSAは、該AI層の周縁に接触し、該AI層の周縁の周りにおいて互いに接着することにより、該AI層からの該揮発性成分の損失を低減または防止するシールを形成する、デバイス。
(項目2)
前記揮発性成分は、有機溶剤であって、前記AI層は、それの中において該有機溶剤が少なくとも部分的に可溶化されるPSA基質を含む、項目1に記載のデバイス。
(項目3)
前記揮発性成分は、DMSO、乳酸エチル、または両方を含み、
前記AI層の前記PSA基質は、ポリアクリレートPSAであり、
前記剥離ライナは、フッ素化またはシリコン化ポリエステル膜、あるいは他のフッ素化またはシリコン化ポリマー、もしくはシリコン化またはフッ素化ポリマーによって裏打ちされた薄片を含み、
前記重層は、ポリイソブチレン感圧接着剤(PIB PSA)を含む、
項目2に記載のデバイス。
(項目4)
重層被覆をさらに含む、項目1、2、または3に記載のデバイス。
(項目5)
前記重層被覆は、ポリアクリレートPSA中間層と、非PSA層とを含む、項目4に記載のデバイス。
(項目6)
前記重層被覆内の前記非PSA層は、ポリウレタン膜、発泡体もしくはスパンボンド構造、ポリオレフィン発泡体、PVC発泡体、または織布もしくは不織布である、項目5に記載のデバイス。
(項目7)
前記AI層と前記重層との間に内部裏地層をさらに含む、項目1、2、3、4、5、または6に記載のデバイス。
(項目8)
経皮的薬物送達デバイスであって、
a)皮膚接触表面と非皮膚接触表面とを有し、揮発性成分を含む、AI層と、
b)該AI層の該非皮膚接触表面に隣接するPIB PSAを含む、重層と
を含む、デバイス。
(項目9)
前記揮発性成分は、DMSO、乳酸エチル、または両方を含む、項目8に記載のデバイス。
(項目10)
前記PIB PSAは、約5乃至約45重量%の架橋PVPと、約10乃至約60重量%の低粘性PIBと、約2乃至約20重量%の高粘性PIBと、約10乃至約60重量%のポリブテンと、約0乃至約20重量%の鉱油とを含む、項目8または9に記載のデバイス。
(項目11)
前記PIB PSAは、約15乃至約30重量%のクロスポビドンと、約30乃至約50重量%の低分子量PIBと、約5乃至約15重量%の高分子量PIBと、100℃で約3900乃至約4200センチストークスの粘性を有する約20乃至約40重量%のポリブテンと、0重量%の鉱油とを含む、項目10に記載のデバイス。
(項目12)
前記PIB PSAは、約20重量%のクロスポビドンと、約40重量%の低分子量PIBと、約8重量%の高分子量PIBと、約32重量%のポリブテンとを含む、項目11に記載のデバイス。
(項目13)
前記AI層の前記皮膚接触面に隣接する剥離ライナをさらに含み、前記重層は、前記PIB PSA上に重層被覆を含む、項目8、9、10、11、または12に記載のデバイス。
(項目14)
前記重層および前記剥離ライナは、前記AI層の周縁の周囲にシールを形成する、項目13に記載のデバイス。
(項目15)
前記AI層の前記非皮膚接触面と前記重層との間に内部裏地層をさらに含む、項目13に記載のデバイス。
(項目16)
経皮的薬物送達デバイスであって、
a)皮膚接触表面と非皮膚接触表面とを有し、AIおよび揮発性成分を含む、AI層と、
b)重層であって、
(i)該AI層の該非皮膚接触表面に隣接するPIB PSAであって、該PIB PSAの周縁は、一部または全部の方向に該AI層の周縁を超えて延在する、PIB PSAと、
(ii)該PIB PSAに対して実質的に不透過性である重層被覆であって、湿気に対して透過性である、重層被覆と
を含む、重層と
を含む、デバイス。
(項目17)
前記重層被覆は、PSA層と、多孔性層とを含む、項目16に記載のデバイス。
(項目18)
前記重層被覆内の前記PSA層は、ポリアクリレートPSAであって、前記多孔性層は、ポリウレタンである、項目17に記載のデバイス。
(項目19)
前記AIは、少なくとも1つのホルモンである、項目1−18のいずれか一項に記載のデバイス。
(項目20)
前記AIは、小分子である、項目1−18のいずれか一項に記載のデバイス。
(項目21)
前記APIは、2つのホルモン(プロゲスチンおよびエストロゲン)である、項目19に記載のデバイス。
(項目22)
前記エストロゲンは、エチニルエストラジオールまたは17ベータエストラジオールであり、前記プロゲスチンは、レボノルゲストレルであり、両方は、ポリマー基質内に存在し、該ポリマー基質は、また、ポリアクリレートPSAと、保湿剤/可塑剤と、1つ以上の皮膚透過促進剤とを含む、項目21に記載のデバイス。
(項目23)
前記1つ以上の皮膚透過促進剤は、DMSOを含む、項目22に記載のデバイス。
(項目24)
前記皮膚透過促進剤は、ヒドロキシ酸の低級(C1−C4)アルキルエステルを含む、項目23に記載のデバイス。
(項目25)
前記皮膚透過促進剤は、DMSOと、乳酸の脂肪(C8−C20)アルコールエステルと、乳酸の低級(C1−C4)アルキルエステルと、C6−C18脂肪酸とを含む、項目22、23、または24に記載のデバイス。
(項目26)
前記ポリアクリレートPSAは、ポリアクリレートコポリマーである、項目22、23、24、または25に記載のデバイス。
(項目27)
前記ポリアクリレートコポリマーは、約3乃至約60重量%の酢酸ビニルを含む、項目26に記載のデバイス。
(項目28)
前記保湿剤/可塑剤は、ポリビニルピロリドン(PVP)を含む、項目22、23、24、25、または26に記載のデバイス。
(項目29)
前記保湿剤/可塑剤は、ポリビニルピロリドン/酢酸ビニル(PVP/VA)コポリマーである、項目28に記載のデバイス。
(項目30)
前記PVPは、前記PVP/VAコポリマー中、約60重量%の量に調剤され、前記酢酸ビニルは、約40重量%の量に調剤される、項目29に記載のデバイス。
(項目31)
前記乳酸の脂肪アルコールエステルは、乳酸ラウリルである、項目25〜30のいずれかに記載のデバイス。
(項目32)
前記乳酸の低級アルキルエステルは、乳酸エチルである、項目31に記載のデバイス。
(項目33)
前記C6−C18脂肪酸は、カプリン酸である、項目25〜32のいずれかに記載のデバイス。
(項目34)
PSAによって剥離ライナにシールされる重層を含み、該剥離ライナを該重層と接触させたまま保持する容器内に封入される、項目1から33のいずれか一項に記載のデバイス。
層6は、一般的には、PSA基質中に、AIと揮発性成分とを含む。揮発性成分は、一般的には、AI層中に少なくとも部分的に溶解される。したがって、例えば、本発明の例示的実施形態では、層6は、AI、アクリルPSA、および揮発性皮膚透過促進剤等の、1つ以上のホルモンを含む。しかしながら、揮発性成分は、また、例えば、AI自体、または溶剤、あるいは担体であり得る。本発明の送達デバイスにおいて有用な経皮的ホルモン組成の例示的調剤は、例えば、米国特許第7,045,145号および米国特許第20070065495号において説明されている。
PSAが、ポリアクリル酸基質を含む場合、上述のように、有機成分は、皮膚およびシステムの非皮膚接触表面を通って漏出することが可能である。非皮膚接触表面を通してのそのような漏出を最小限にするために、内部裏地層が利用可能である。重層内へのAI層の成分の吸収を抑制する本層は、図1の層5として示される。
剥離ライナの表面積は、AI層よりも大きい。これは、図1に見られ、層3の直径(円形デバイスの場合)、または幅および長さ(多角形デバイスの場合)は、一部または全部の方向にAI層を超えて延在するように、層5および6よりも大きい。
本例示的実施形態では、重層は、図1において層1、2、および3と称される3つの構成層を含む。重層は、揮発性成分の溶解度が、AI基質内の同成分の溶解度よりも低い、好ましくは、大幅に低い、PSAを含む。したがって、例えば、揮発性成分がDMSOまたは乳酸エチルである場合、PIB PSAが選択されてもよい。図1を参照すると、PIB PSA層は、層3である。概して、そのようなPIB PSAは、低乃至中間分子量および高分子量PIBと、可塑剤、例えば、ポリブテンと、親水コロイド、例えば、架橋ポリビニルピロリジンとの混合を含む。有用なPIBは、例えば、Oppanol(登録商標) PIB(BASF)を含み、平均分子量40,000乃至4,000,000を有する。
PSAの流動を抑制または防止する中間層との使用に関する。
実施例1は、本発明の経皮送達システムを加工するための方法の1つの説明である。また、他の方法も使用可能であることを理解されたい。本実施例では、パートAは、内部裏地/AI層/剥離ライナ積層の調製を示す。パートBは、発泡体/アクリルPSA/PIB PSA重層構造の加工を示す。パートCは、パートAおよびBで調製された積層を利用する、本発明の一体型デバイスまたはシステムの加工を示す。
LTSV/LTH装置、ならびにWerner Mathis AG(Zurich,Switzerland)から市販の他の実験用被膜デバイスが利用されてもよい。他の好適デバイスは、Chemsultants,Inc.(Mentor,OH)から市販の器具を含むが、それに限定されない。
経皮的ホルモン送達デバイスは、内部裏地層と、AI層と、剥離ライナとを含むように調製した。AI層は、ポリマー基質PSAとしてDuro Tak 87−4098と、保湿剤としてPVP/VA−S360と、皮膚透過促進剤としてジメチルスルホキシド(DMSO)、乳酸ラウリル(Ceraphyl(登録商標) 31)、乳酸エチル、およびカプリン酸と、AIとして、レボノルゲストレルおよびエチニルエストラジオールとを含んでいた。
Claims (27)
- 経皮的薬物送達デバイスであって、
(a)皮膚接触表面と非皮膚接触表面とを有する活性成分(AI)層であって、前記AI層は、活性成分および揮発性成分を含む非水溶性ポリマー感圧接着剤(PSA)基質である、AI層と、
(b)前記AI層の前記皮膚接触表面に隣接する剥離ライナであって、前記剥離ライナは、前記揮発性成分に対して不透過性であり、それの周縁は、全方向に前記AI層の周縁を超えて延在する、剥離ライナと、
(c)前記AI層の前記非皮膚接触表面に隣接する非水溶性ポリマーPSAを含む重層であって、それの周縁は、全方向に前記AI層の周縁を超えて延在する、重層と、
(d)前記AI層と前記重層との間の内部裏地層と
を含み、
前記重層の前記PSAにおける前記揮発性成分の可溶性は、前記AI層の前記PSAにおける前記揮発性成分の可溶性よりも低く、
前記剥離ライナおよび前記重層の前記PSAは、前記AI層の周縁に接触し、前記AI層の周縁の周りにおいて互いに接着することにより、前記AI層からの前記揮発性成分の損失を低減または防止するシールを形成する、デバイス。 - 前記揮発性成分は、有機溶剤であって、前記AI層は、それの中において前記有機溶剤が少なくとも部分的に可溶化されるPSA基質を含む、請求項1に記載のデバイス。
- 前記揮発性成分は、DMSO、乳酸エチル、または両方を含み、
前記AI層の前記PSA基質は、ポリアクリレートPSAであり、
前記剥離ライナは、フッ素化またはシリコン化ポリエステル膜、あるいは他のフッ素化またはシリコン化ポリマー、もしくはシリコン化またはフッ素化ポリマーによって裏打ちされた薄片を含み、
前記重層は、ポリイソブチレン感圧接着剤(PIB PSA)を含む、
請求項2に記載のデバイス。 - 重層被覆をさらに含む、請求項1〜3のいずれかに記載のデバイス。
- 前記重層被覆は、ポリアクリレートPSA中間層と、非PSA層とを含む、請求項4に記載のデバイス。
- 前記重層被覆内の前記非PSA層は、ポリウレタン膜、発泡体もしくはスパンボンド構造、ポリオレフィン発泡体、PVC発泡体、または織布もしくは不織布である、請求項5に記載のデバイス。
- 前記重層の前記PSAは、PIB PSAである、請求項1に記載のデバイス。
- 前記重層の周縁は、全部の方向に前記AI層の周縁を超えて延在し、
前記重層は、前記PIB PSAに対して実質的に不透過性である重層被覆であって、湿気に対して透過性である、重層被覆を含む、請求項7に記載のデバイス。 - 前記揮発性成分は、DMSO、乳酸エチル、または両方を含む、請求項7に記載のデバイス。
- 前記PIB PSAは、5乃至45重量%の架橋PVPと、10乃至60重量%の低粘性PIBと、2乃至20重量%の高粘性PIBと、10乃至60重量%のポリブテンと、0乃至20重量%の鉱油とを含む、請求項7または9に記載のデバイス。
- 前記PIB PSAは、15乃至30重量%のクロスポビドンと、30乃至50重量%の低分子量PIBと、5乃至15重量%の高分子量PIBと、100℃で3900乃至4200mm2/s(センチストークス)の粘性を有する20乃至40重量%のポリブテンと、0重量%の鉱油とを含む、請求項10に記載のデバイス。
- 前記重層被覆は、PSA層と、多孔性層とを含む、請求項8に記載のデバイス。
- 前記重層被覆内の前記PSA層は、ポリアクリレートPSAであって、前記多孔性層は、ポリウレタンである、請求項12に記載のデバイス。
- 前記AIは、(i)小分子であるか、または、(ii)少なくとも2つのホルモンである、請求項1〜13のいずれかに記載のデバイス。
- 前記AIは、2つのホルモン(プロゲスチンおよびエストロゲン)である、請求項14に記載のデバイス。
- 前記エストロゲンは、エチニルエストラジオールまたは17ベータエストラジオールであり、前記プロゲスチンは、レボノルゲストレルであり、両方は、ポリマー基質内に存在し、前記ポリマー基質は、また、ポリアクリレートPSAと、保湿剤/可塑剤と、1つ以上の皮膚透過促進剤とを含む、請求項15に記載のデバイス。
- 前記1つ以上の皮膚透過促進剤は、DMSOを含み、かつ/または、
前記1つ以上の皮膚透過促進剤は、DMSOと、乳酸の脂肪(C8−C20)アルコールエステルと、乳酸の低級(C1−C4)アルキルエステルと、C6−C18脂肪酸とを含む、請求項14〜16のいずれかに記載のデバイス。 - 前記1つ以上の皮膚透過促進剤は、DMSOと、ヒドロキシ酸の低級(C1−C4)アルキルエステルとを含む、請求項14〜16のいずれかに記載のデバイス。
- 前記乳酸の脂肪(C8−C20)アルコールエステルは、乳酸ラウリルである、請求項17に記載のデバイス。
- 前記乳酸の低級(C1−C4)アルキルエステルは、乳酸エチルである、請求項17または19に記載のデバイス。
- 前記C6−C18脂肪酸は、カプリン酸である、請求項17、19または20のいずれかに記載のデバイス。
- 前記ポリアクリレートPSAは、ポリアクリレートコポリマーである、請求項14〜21のいずれかに記載のデバイス。
- 前記ポリアクリレートコポリマーは、3乃至60重量%の酢酸ビニルを含む、請求項22に記載のデバイス。
- 前記保湿剤/可塑剤は、ポリビニルピロリドン(PVP)を含む、請求項14〜23のいずれかに記載のデバイス。
- 前記保湿剤/可塑剤は、ポリビニルピロリドン/酢酸ビニル(PVP/VA)コポリマーである、請求項14〜23のいずれかに記載のデバイス。
- 前記PVPは、前記PVP/VAコポリマー中、60重量%の量に調剤され、前記酢酸ビニルは、40重量%の量に調剤される、請求項25に記載のデバイス。
- PSAによって剥離ライナにシールされる重層を含み、前記剥離ライナを前記重層と接触させたまま保持する容器内に封入される、請求項1〜26のいずれかに記載のデバイス。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94875707P | 2007-07-10 | 2007-07-10 | |
US60/948,757 | 2007-07-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010516238A Division JP5603235B2 (ja) | 2007-07-10 | 2008-07-10 | イン・サイチュシールを有する経皮送達デバイス |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014159468A JP2014159468A (ja) | 2014-09-04 |
JP6072725B2 true JP6072725B2 (ja) | 2017-02-01 |
Family
ID=40229053
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010516238A Active JP5603235B2 (ja) | 2007-07-10 | 2008-07-10 | イン・サイチュシールを有する経皮送達デバイス |
JP2014097353A Active JP6072725B2 (ja) | 2007-07-10 | 2014-05-09 | イン・サイチュシールを有する経皮送達デバイス |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010516238A Active JP5603235B2 (ja) | 2007-07-10 | 2008-07-10 | イン・サイチュシールを有する経皮送達デバイス |
Country Status (13)
Country | Link |
---|---|
US (3) | US8246978B2 (ja) |
EP (1) | EP2167002B1 (ja) |
JP (2) | JP5603235B2 (ja) |
CN (1) | CN101801321B (ja) |
AU (1) | AU2008275101B2 (ja) |
BR (1) | BRPI0814697B8 (ja) |
CA (1) | CA2692884C (ja) |
EA (1) | EA020208B1 (ja) |
ES (1) | ES2581652T3 (ja) |
GE (1) | GEP20125717B (ja) |
HK (1) | HK1142798A1 (ja) |
NZ (1) | NZ582565A (ja) |
WO (1) | WO2009009649A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001292683A1 (en) | 2000-09-15 | 2002-03-26 | Bruder Healthcare Company | Wound and therapy compress and dressing |
US10105259B2 (en) | 2000-09-15 | 2018-10-23 | Bruder Healthcare Company, Llc | Wound and therapy compress and dressing |
US9925087B2 (en) | 2000-09-15 | 2018-03-27 | Bruder Healthcare Company, Llc | Wound and therapy compress and dressing |
EP2167001A4 (en) * | 2007-07-10 | 2012-10-31 | Agile Therapeutics Inc | THERMAL DELIVERY DEVICE WITH ULTRASONIC WELDING |
EP2167002B1 (en) | 2007-07-10 | 2016-04-20 | Agile Therapeutics, Inc. | Dermal delivery device with in situ seal |
US8859001B2 (en) * | 2007-10-18 | 2014-10-14 | Mia Levite | Fenoldopam formulations and pro-drug derivatives |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
WO2011088072A2 (en) * | 2010-01-14 | 2011-07-21 | Agile Therapeutics, Inc. | Dermal delivery device |
AU2010200556B2 (en) * | 2010-02-15 | 2012-02-02 | Oncobeta International Gmbh | Brachytherapy method of treating skin tumours using a tailor-made radioactive source |
JPWO2011118683A1 (ja) * | 2010-03-25 | 2013-07-04 | 東洋化学株式会社 | 医用貼付剤 |
EP2759294B1 (en) * | 2011-09-22 | 2017-11-01 | Samyang Biopharmaceuticals Corporation | Formulation for percutaneous administration containing Fentanyl and analague thereof |
MX353713B (es) | 2011-11-04 | 2018-01-24 | Agile Therapeutics Inc | Composiciones de administracion dermica y metodos. |
JP6345120B2 (ja) | 2012-01-27 | 2018-06-20 | アジル・セラピューティクス・インコーポレイテッドAgile Therapeutics, Inc. | 経皮ホルモン送達 |
US9539201B2 (en) | 2012-04-20 | 2017-01-10 | KAT Transdermals LLC | Selegiline transdermal system |
CA2894696A1 (en) * | 2012-12-21 | 2014-06-26 | Teikoku Pharma Usa, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
AR094289A1 (es) | 2012-12-28 | 2015-07-22 | Noven Pharma | Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol |
WO2014143139A1 (en) | 2013-03-15 | 2014-09-18 | Bruder Healthcare Company | Wound and therapy compress and dressing |
EP2921184A1 (de) | 2014-03-19 | 2015-09-23 | LTS LOHMANN Therapie-Systeme AG | Überpflaster mit verbesserter Verträglichkeit und einer langen Haftungsdauer und Verfahren zu seiner Herstellung |
EP3134499A4 (en) * | 2014-04-23 | 2018-02-28 | Steinemann, Anne | Cleaning formulations for chemically sensitive individuals: compositions and methods |
EP3067050A1 (en) * | 2015-03-13 | 2016-09-14 | Acino AG | Transdermal therapeutic system with an overtape comprising two adhesive layers |
WO2017135474A1 (en) * | 2016-02-05 | 2017-08-10 | Nitto Denko Corporation | Transdermal permeant application device |
US12011388B2 (en) | 2016-03-01 | 2024-06-18 | The Hilsinger Company Parent, Llc | Therapeutic thermal compress with phase-change material |
WO2017191680A1 (ja) * | 2016-05-02 | 2017-11-09 | 小林製薬株式会社 | 発熱具 |
JP7174632B2 (ja) | 2016-06-23 | 2022-11-17 | コリウム, インコーポレイテッド | 親水性ドメインおよび疎水性ドメインならびに処置剤との接着剤マトリックス |
WO2018022818A1 (en) | 2016-07-27 | 2018-02-01 | Corium International, Inc. | Memantine transdermal delivery systems |
KR102406528B1 (ko) | 2016-07-27 | 2022-06-08 | 코리움, 인크. | 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된 경피성 전달 |
CN109789134A (zh) | 2016-07-27 | 2019-05-21 | 考里安国际公司 | 与口服递送药代动力学生物等效的透皮递送系统 |
USD871598S1 (en) | 2016-11-30 | 2019-12-31 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
USD844795S1 (en) | 2016-11-30 | 2019-04-02 | Bruder Healthcare Company, Llc | Therapeutic eye mask |
CA3086163A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
CN113248586B (zh) * | 2021-04-23 | 2022-08-30 | 武汉大学 | 褐飞虱pib14蛋白及其编码基因在调控植物抗褐飞虱中的应用 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59108614U (ja) * | 1983-01-05 | 1984-07-21 | 久光製薬株式会社 | 貼付剤構造 |
US4710191A (en) * | 1985-12-16 | 1987-12-01 | Jonergin, Inc. | Therapeutic device for the administration of medicaments |
JPS62212321A (ja) * | 1986-03-14 | 1987-09-18 | Tadashi Ijima | 治療具 |
US4917676A (en) * | 1986-11-20 | 1990-04-17 | Ciba-Geigy Corporation | User-activated transdermal therapeutic system |
DE3643987A1 (de) * | 1986-12-22 | 1988-06-23 | Lohmann Therapie Syst Lts | Basische, wirkstoffdurchlaessige haftklebende polymermasse, insbesondere zum einsatz mit basischen wirkstoffen, verfahren zu ihrer herstellung und ihre verwendung |
US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
US4983395A (en) * | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4849224A (en) * | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
JPH01224312A (ja) * | 1988-03-01 | 1989-09-07 | Tadashi Ijima | 治療具 |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5008110A (en) * | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5788983A (en) * | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
DE3933460A1 (de) * | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | Oestrogenhaltiges wirkstoffpflaster |
JPH0794583B2 (ja) * | 1989-12-15 | 1995-10-11 | 株式会社大塚製薬工場 | 高含水高分子ゲル |
US5252588A (en) * | 1990-04-27 | 1993-10-12 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation |
US5064422A (en) * | 1990-10-18 | 1991-11-12 | Bertek, Inc. | Twin patch applicator |
US5122382A (en) * | 1990-10-29 | 1992-06-16 | Alza Corporation | Transdermal contraceptive formulations, methods and devices |
US5227169A (en) * | 1991-05-17 | 1993-07-13 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
US5273756A (en) | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
US5676968A (en) * | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
EP0593807A1 (en) * | 1992-10-22 | 1994-04-27 | LTS Lohmann Therapie-Systeme GmbH & Co. KG | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation |
US5268179A (en) * | 1992-02-14 | 1993-12-07 | Ciba-Geigy Corporation | Ultrasonically sealed transdermal drug delivery systems |
US6010715A (en) * | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US6024975A (en) * | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US5756117A (en) | 1992-04-08 | 1998-05-26 | International Medical Asscociates, Inc. | Multidose transdermal drug delivery system |
DE4227989A1 (de) * | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
US5714543A (en) * | 1994-01-13 | 1998-02-03 | Bristol-Myers Squibb Company | Water soluble polymer additives for polyurethane-based pressure sensitive adhesives |
ATE246909T1 (de) * | 1994-03-07 | 2003-08-15 | Theratech Inc | Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung |
IL113034A (en) * | 1994-04-05 | 2000-02-17 | Astra Ab | Topical dressing |
US5851549A (en) * | 1994-05-25 | 1998-12-22 | Becton Dickinson And Company | Patch, with system and apparatus for manufacture |
EP0799029A1 (en) * | 1994-12-21 | 1997-10-08 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
CN2245437Y (zh) * | 1995-08-24 | 1997-01-22 | 福祥纺织股份有限公司 | 皮肤贴片 |
KR100213465B1 (ko) * | 1996-11-01 | 1999-08-02 | 최좌진 | 케토프로펜 패취 조성물 |
ATE226816T1 (de) * | 1996-07-03 | 2002-11-15 | Alza Corp | Vorrichtungen zur arzneistoffabgabe und herstellungsverfahren |
US7150881B2 (en) * | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
JP2000514065A (ja) * | 1997-07-03 | 2000-10-24 | アルザ コーポレイション | ドラッグデリバリーディバイスとその製造法 |
US6086912A (en) * | 1998-02-11 | 2000-07-11 | Gilman; Marvin S. | Topical drug delivery system |
US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
US7045145B1 (en) * | 1999-11-24 | 2006-05-16 | Agile Therapeutics, Inc. | Transdermal contraceptive delivery system and process |
US20020037311A1 (en) * | 2000-06-01 | 2002-03-28 | David Fikstad | Transdermal delivery of lasofoxifene |
AU2001292683A1 (en) | 2000-09-15 | 2002-03-26 | Bruder Healthcare Company | Wound and therapy compress and dressing |
US6682757B1 (en) * | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
WO2002072720A1 (fr) * | 2001-03-08 | 2002-09-19 | Matsushita Electric Industrial Co., Ltd. | Enregistrement a jet d'encre, solvant utilise avec cette encre, cartouche et dispositif d'enregistrement comportant cette encre |
JP2004538090A (ja) | 2001-07-23 | 2004-12-24 | ノボバスキュラー インコーポレーテッド | 酸化窒素放出ePTFEコーティング医療用デバイスサンドイッチ |
CA2453013C (en) | 2002-12-13 | 2011-02-15 | Gary W. Cleary | Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
US7612248B2 (en) * | 2002-12-19 | 2009-11-03 | 3M Innovative Properties Company | Absorbent medical articles |
WO2004075933A2 (en) * | 2003-02-26 | 2004-09-10 | Lavipharm S.A. | Devices for releasing volatile substances and methods of producing the devices |
CN1291759C (zh) * | 2003-07-31 | 2006-12-27 | 天津大学 | 聚n-乙烯基吡咯烷酮与聚乙烯醇共混压敏胶及其应用 |
US20070037751A1 (en) * | 2003-08-06 | 2007-02-15 | Gastrotech Pharma A/S | Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
ME00114B (me) * | 2003-10-28 | 2011-02-10 | Noven Pharma | Kompozicije i postupci za kontrolisanje gubitka i oslobađanja lijeka u transdermalnim sistemima oslobađanja lijeka |
JP4809062B2 (ja) * | 2004-01-30 | 2011-11-02 | 久光製薬株式会社 | カバー材及びカバー材付き貼付剤 |
US20050232983A1 (en) * | 2004-04-14 | 2005-10-20 | Indevus Pharmaceuticals, Inc. | Transdermal patch |
JP2006169160A (ja) * | 2004-12-15 | 2006-06-29 | Yuutoku Yakuhin Kogyo Kk | 外用貼付剤およびその製造方法 |
KR20070121666A (ko) * | 2005-02-14 | 2007-12-27 | 노이로제스엑스, 인코포레이티드 | Trpv1 작용제의 전달용 장치 |
JP4921739B2 (ja) * | 2005-08-10 | 2012-04-25 | 久光製薬株式会社 | 皮膚刺激を低減した貼付剤 |
US20070098772A1 (en) * | 2005-09-23 | 2007-05-03 | Westcott Tyler D | Transdermal norelgestromin delivery system |
EP2674188B1 (en) | 2007-01-22 | 2017-03-01 | Nitto Denko Corporation | Transdermal permeant delivery system |
WO2008148786A1 (en) | 2007-06-04 | 2008-12-11 | Coloplast A/S | A method for manufacturing a patterned adhesive layer |
EP2167002B1 (en) | 2007-07-10 | 2016-04-20 | Agile Therapeutics, Inc. | Dermal delivery device with in situ seal |
EP2167001A4 (en) * | 2007-07-10 | 2012-10-31 | Agile Therapeutics Inc | THERMAL DELIVERY DEVICE WITH ULTRASONIC WELDING |
-
2008
- 2008-07-10 EP EP08826282.9A patent/EP2167002B1/en active Active
- 2008-07-10 WO PCT/US2008/069618 patent/WO2009009649A1/en active Application Filing
- 2008-07-10 US US12/668,322 patent/US8246978B2/en active Active
- 2008-07-10 NZ NZ582565A patent/NZ582565A/en unknown
- 2008-07-10 CA CA2692884A patent/CA2692884C/en active Active
- 2008-07-10 ES ES08826282.9T patent/ES2581652T3/es active Active
- 2008-07-10 BR BRPI0814697A patent/BRPI0814697B8/pt active IP Right Grant
- 2008-07-10 EA EA201070123A patent/EA020208B1/ru not_active IP Right Cessation
- 2008-07-10 JP JP2010516238A patent/JP5603235B2/ja active Active
- 2008-07-10 AU AU2008275101A patent/AU2008275101B2/en active Active
- 2008-07-10 CN CN200880106390.3A patent/CN101801321B/zh not_active Expired - Fee Related
- 2008-07-10 GE GEAP200811682A patent/GEP20125717B/en unknown
-
2010
- 2010-09-29 HK HK10109364.7A patent/HK1142798A1/zh unknown
-
2012
- 2012-07-19 US US13/553,362 patent/US8747888B2/en active Active
-
2014
- 2014-04-29 US US14/264,427 patent/US20140350493A1/en not_active Abandoned
- 2014-05-09 JP JP2014097353A patent/JP6072725B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010533199A (ja) | 2010-10-21 |
WO2009009649A1 (en) | 2009-01-15 |
US20130018337A1 (en) | 2013-01-17 |
CA2692884C (en) | 2016-09-20 |
US20100255072A1 (en) | 2010-10-07 |
US8246978B2 (en) | 2012-08-21 |
CA2692884A1 (en) | 2009-01-15 |
US20140350493A1 (en) | 2014-11-27 |
NZ582565A (en) | 2012-07-27 |
BRPI0814697B8 (pt) | 2021-05-25 |
EP2167002A4 (en) | 2012-11-28 |
CN101801321A (zh) | 2010-08-11 |
CN101801321B (zh) | 2014-07-02 |
JP2014159468A (ja) | 2014-09-04 |
GEP20125717B (en) | 2012-12-25 |
ES2581652T3 (es) | 2016-09-06 |
US8747888B2 (en) | 2014-06-10 |
BRPI0814697A2 (pt) | 2017-06-06 |
EA201070123A1 (ru) | 2010-06-30 |
AU2008275101A1 (en) | 2009-01-15 |
JP5603235B2 (ja) | 2014-10-08 |
BRPI0814697B1 (pt) | 2020-11-17 |
HK1142798A1 (zh) | 2010-12-17 |
AU2008275101B2 (en) | 2014-08-21 |
EA020208B1 (ru) | 2014-09-30 |
EP2167002B1 (en) | 2016-04-20 |
EP2167002A1 (en) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6072725B2 (ja) | イン・サイチュシールを有する経皮送達デバイス | |
US20210030694A1 (en) | Dermal Delivery Device | |
US20210023092A1 (en) | Transdermal Delivery | |
WO2011088072A2 (en) | Dermal delivery device | |
CA2756222A1 (en) | Transdermal delivery | |
US20140256690A1 (en) | Contraceptive method | |
US20180104259A1 (en) | Transdermal contraceptive hormones delivery | |
CA2740002C (en) | Transdermal delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150806 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150911 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160307 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160606 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160907 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161205 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6072725 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |